Evidence map›Paper›PMID 27181226›Full record

ArticleExperimental eye research2016

Dimethylarginine dimethylaminohydrolase-2 deficiency promotes vascular regeneration and attenuates pathological angiogenesis.

Clemens Lange, Freya Mowat, Haroon Sayed, Manjit Mehad, Lucie Duluc, Sophie Piper, Ulrich Luhmann, Manasi Nandi, Peter Kelly, Alexander Smith and 3 more

Open access · hybridAbstract read
In one paragraph

Article in Experimental eye research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 36 citations in OpenAlex.

  1. Review
  2. Article
  3. Transcriptional Comparison of Human and Murine Retinal Neovascularization.Investigative ophthalmology & visual science · 2023
    Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Clemens LangeDepartment of Genetics, UCL Institute of Ophthalmology, 11-43 Bath Street, London, UK; Eye Center, University Hospital Freiburg, Germany.
Freya MowatDepartment of Genetics, UCL Institute of Ophthalmology, 11-43 Bath Street, London, UK.
Haroon SayedDepartment of Genetics, UCL Institute of Ophthalmology, 11-43 Bath Street, London, UK.
Manjit MehadDepartment of Genetics, UCL Institute of Ophthalmology, 11-43 Bath Street, London, UK.
Lucie DulucThe Nitric Oxide Signalling Group, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Hospital, Du Cane Road, London, UK.
Sophie PiperThe Nitric Oxide Signalling Group, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Hospital, Du Cane Road, London, UK.
Ulrich LuhmannDepartment of Genetics, UCL Institute of Ophthalmology, 11-43 Bath Street, London, UK.
Manasi NandiInstitute of Pharmaceutical Science, King's College London, UK.
Peter KellyThe Nitric Oxide Signalling Group, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Hospital, Du Cane Road, London, UK.
Alexander SmithDepartment of Genetics, UCL Institute of Ophthalmology, 11-43 Bath Street, London, UK.
Robin AliDepartment of Genetics, UCL Institute of Ophthalmology, 11-43 Bath Street, London, UK.
James LeiperThe Nitric Oxide Signalling Group, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Hospital, Du Cane Road, London, UK.
James BainbridgeDepartment of Genetics, UCL Institute of Ophthalmology, 11-43 Bath Street, London, UK. Electronic address: j.bainbridge@ucl.ac.uk.
University College London · GBHammersmith Hospital · GBImperial College London · GBKing's College London · GBUniversity Medical Center Freiburg · DE

Funding

British Heart Foundation PG/02/165/14797British Heart Foundation RG/02/005Department of Health NIHR-RP-011-003Medical Research Council MC_U120097118Medical Research Council MR/K024000/1Medical Research Council MR/L022699/1Wellcome Trust 074617/Z/04/Z
6 · The paper itself

Abstract

Ischemia-induced angiogenesis is critical for tissue repair, but aberrant neovascularization in the retina causes severe sight impairment. Nitric oxide (NO) has been implicated in neovascular eye disease because of its pro-angiogenic properties in the retina. Nitric oxide production is inhibited endogenously by asymmetric dimethylarginines (ADMA and L-NMMA) which are metabolized by dimethylarginine dimethylaminohydrolase (DDAH) 1 and 2. The aim of this study was to determine the roles of DDAH1, DDAH2, ADMA and L-NMMA in retinal ischemia-induced angiogenesis. First, DDAH1, DDAH2, ADMA and L-NMMA levels were determined in adult C57BL/6J mice. The results obtained revealed that DDAH1 was twofold increased in the retina compared to the brain and the choroid. DDAH2 expression was approximately 150 fold greater in retinal and 70 fold greater in choroidal tissue compared to brain tissue suggesting an important tissue-specific role for DDAH2 in the retina and choroid. ADMA and L-NMMA levels were similar in the retina and choroid under physiological conditions. Next, characterization of DDAH1(+/-) and DDAH2(-/-) deficient mice by in vivo fluorescein angiography, immunohistochemistry and electroretinography revealed normal neurovascular function compared with wildtype control mice. Finally, DDAH1(+/-) and DDAH2(-/-) deficient mice were studied in the oxygen-induced retinopathy (OIR) model, a model used to emulate retinal ischemia and neovascularization, and VEGF and ADMA levels were quantified by ELISA and liquid chromatography tandem mass spectrometry. In the OIR model, DDAH1(+/-) exhibited a similar phenotype compared to wildtype controls. DDAH2 deficiency, in contrast, resulted in elevated retinal ADMA which was associated with attenuated aberrant angiogenesis and improved vascular regeneration in a VEGF independent manner. Taken together this study suggests, that in retinal ischemia, DDAH2 deficiency elevates ADMA, promotes vascular regeneration and protects against aberrant angiogenesis. Therapeutic inhibition of DDAH2 may therefore offer a potential therapeutic strategy to protect sight by promoting retinal vascular regeneration and preventing pathological angiogenesis.

Indexed as

AmidohydrolasesAnimalsChoroidal NeovascularizationDisease Models, AnimalElectroretinographyImmunohistochemistryIschemiaMiceMice, Inbred C57BLMice, KnockoutNeovascularization, PathologicNitric OxideRetinal NeovascularizationVascular Endothelial Growth Factor AAmidohydrolasesdimethylargininaseNitric OxideVascular Endothelial Growth Factor AADMAAngiogenesisDDAH1DDAH2Nitric oxideRetinal neovascularization

Identifiers

PMID27181226
PMCPMC4912010
OpenAlexW2363293470

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.